Sophie de Guibert
YOU?
Author Swipe
View article: <i>NOTCH1</i> Mutation Is Associated With Response to Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: A Retrospective Study
<i>NOTCH1</i> Mutation Is Associated With Response to Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: A Retrospective Study Open
Background Chronic lymphocytic leukemia (CLL) treatment choice remains a challenge in the era of molecular biology and targeted therapy. Methods We conducted a bicentric retrospective analysis of the impact of NOTCH1 mutation according to …
View article: Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA Open
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. …
View article: Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial
Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial Open
Richter transformation (RT) is an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia. Here we investigated the anti-CD3/anti-CD19 T-cell-engager blinatumomab after R-CHOP (i.e. rituximab, cyclophosphamide, doxorub…
View article: Remission after CAR T‐cell therapy: Do lymphoma patients recover a normal life?
Remission after CAR T‐cell therapy: Do lymphoma patients recover a normal life? Open
Chimeric antigen receptor T cells (CAR T cells) can induce prolonged remission in a substantial subset of patients with relapse/refractory lymphoma. However, little is known about patients' life after CAR T‐cell therapy. We prospectively a…
View article: Impact of diagnostic investigations in the management of CAR T-cell–associated neurotoxicity
Impact of diagnostic investigations in the management of CAR T-cell–associated neurotoxicity Open
International guidelines regarding the management of immune effector cell–associated neurotoxicity syndrome (ICANS) recommend several diagnostic investigations, including magnetic resonance imaging (MRI), lumbar puncture (LP), and electroe…
View article: Remote monitoring of CAR T-cell treated patients by a specialized nurse to detect and manage late complications: report of the CARAMA program
Remote monitoring of CAR T-cell treated patients by a specialized nurse to detect and manage late complications: report of the CARAMA program Open
Background CAR T-cells have been approved for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), acute lymphoblastic leukemia (ALL), and multiple myeloma …
View article: Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids Open
View article: Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma
Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma Open
Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy, was approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL) based on the results from pivotal Cohorts 1+2 of ZUMA-1 (NCT023482…
View article: P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY
P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY Open
Background: ZANU is a next-generation Bruton tyrosine kinase inhibitor (BTKi) designed to minimize off-target binding and limit associated side effects that is approved in the US and EU for CLL/SLL. Results from the SEQUOIA study (NCT03336…
View article: P1407: REMOTE MONITORING OF CAR T-CELL TREATED PATIENTS BY A SPECIALIZED NURSE TO DETECT AND MANAGE LATE COMPLICATIONS: REPORT OF THE CARAMA PROGRAM
P1407: REMOTE MONITORING OF CAR T-CELL TREATED PATIENTS BY A SPECIALIZED NURSE TO DETECT AND MANAGE LATE COMPLICATIONS: REPORT OF THE CARAMA PROGRAM Open
Topic: 25. Gene therapy, cellular immunotherapy and vaccination - Clinical Background: CAR T-cells have been approved for the treatment of relapse/refractory (R/R) large B-cell lymphoma (LBCL), mantle cell lymphoma (MCL), follicular lympho…
View article: P1687: LIFE AFTER CAR T-CELLS: DO PATIENTS RECOVER A NORMAL LIFE?
P1687: LIFE AFTER CAR T-CELLS: DO PATIENTS RECOVER A NORMAL LIFE? Open
Topic: 35. Quality of life and palliative care Background: CD19 CAR-T cells have been approved for the treatment of relapse/refractory (R/R) lymphoma. Although CAR T-cells are able to induce prolonged remission (and potentially cure) in a …
View article: REMISSION AFTER CAR T‐CELLS: DO PATIENTS RECOVER A NORMAL LIFE?
REMISSION AFTER CAR T‐CELLS: DO PATIENTS RECOVER A NORMAL LIFE? Open
Introduction: CD19 CAR T-cells can induce prolonged remission in a significant number of patients with relapse/refractory (R/R) lymphoma. However, little is known about patients' life after CAR T-cell therapy. Here, we conducted a prospect…
View article: Remote monitoring of CAR T‐cell treated patients by a specialized nurse to detect and manage late complications: report of the CARAMA program
Remote monitoring of CAR T‐cell treated patients by a specialized nurse to detect and manage late complications: report of the CARAMA program Open
Introduction: CAR T-cells have been approved for the treatment of relapse/refractory (R/R) large B-cell lymphoma (LBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), acute lymphoblastic leukemia (ALL), and multiple myeloma (MM). A…
View article: ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT‐NAïVE (TN) CLL/SLL: EXTENDED FOLLOW‐UP OF THE SEQUOIA STUDY
ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT‐NAïVE (TN) CLL/SLL: EXTENDED FOLLOW‐UP OF THE SEQUOIA STUDY Open
Introduction: Zanu, a next-generation Bruton tyrosine kinase inhibitor (BTKi), demonstrated superior progression-free survival (PFS) by independent review versus BR in pts with TN CLL/SLL without (w/o) del(17p) in the SEQUOIA study (NCT033…
View article: A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial Open
In previously untreated, medically fit patients with chronic lymphocytic leukemia (CLL), research is focused on developing fixed-duration strategies to improve long-term outcomes while sparing patients from serious toxicities. The ICLL-07 …
View article: Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists
Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists Open
View article: <scp>TP53</scp> mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia
<span>TP53</span> mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia Open
International audience
View article: Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma Open
Summary ZUMA‐1 (NCT02348216) examined the safety and efficacy of axicabtagene ciloleucel (axi‐cel), an autologous CD19‐directed chimaeric antigen receptor (CAR)‐T cell therapy, in refractory large B‐cell lymphoma. To reduce treatment‐relat…
View article: CLINICAL ACTIVITY OF LONCASTUXIMAB TESIRINE PLUS IBRUTINIB IN NON‐HODGKIN LYMPHOMA: UPDATED LOTIS 3 PHASE 1 RESULTS
CLINICAL ACTIVITY OF LONCASTUXIMAB TESIRINE PLUS IBRUTINIB IN NON‐HODGKIN LYMPHOMA: UPDATED LOTIS 3 PHASE 1 RESULTS Open
Peer Reviewed
View article: LIFE AFTER CAR‐T CELLS: A PROSPECTIVE STUDY EVALUATING THE PERSONAL, SOCIAL AND PROFESSIONAL OUTCOMES AFTER CAR‐T CELL THERAPY IN LYMPHOMA PATIENTS
LIFE AFTER CAR‐T CELLS: A PROSPECTIVE STUDY EVALUATING THE PERSONAL, SOCIAL AND PROFESSIONAL OUTCOMES AFTER CAR‐T CELL THERAPY IN LYMPHOMA PATIENTS Open
Introduction: CD19 CAR-T cells have been approved for the treatment of relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). With these adoptive immunotherapies, about 30-40% of patients achieve prolonged remissions, most of whom…
View article: Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study
Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study Open
View article: Altitude healing effect in severe asthmatic children
Altitude healing effect in severe asthmatic children Open
View article: A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial
A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial Open
Trials assessing first-line, fixed-duration approaches in chronic lymphocytic leukemia (CLL) are yielding promising activity, but few long-term data are available. We report follow-up data from a phase 2 trial (ICLL07 FILO) in previously u…
View article: Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO) Open
As a result of significant recent developments, the management of patients with chronic lymphocytic leukemia (CLL) is changing, and new therapeutic options will continue to emerge in the near future. The recommendations of the French Innov…
View article: Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study
Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study Open
International audience
View article: Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial Open
View article: Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial Open
View article: PF373 IMPACT OF ATM ALTERATIONS ON CHRONIC LYMPHOCYTIC LEUKEMIA IN GENERAL PRACTICE IN THE AREA OF NEXT GENERATION SEQUENCING
PF373 IMPACT OF ATM ALTERATIONS ON CHRONIC LYMPHOCYTIC LEUKEMIA IN GENERAL PRACTICE IN THE AREA OF NEXT GENERATION SEQUENCING Open
Background: Chronic Lymphocytic Leukemia (CLL) is characterized by a very heterogeneous clinical course. Del11q22–23 affecting ATM gene is the most common cytogenetic abnormality associated with poor prognosis. Clinical significance of ATM…
View article: Ibrutinib and idelalisib in the management of CLL‐associated autoimmune cytopenias: a study from the FILO group
Ibrutinib and idelalisib in the management of CLL‐associated autoimmune cytopenias: a study from the FILO group Open
International audience
View article: Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Open